Frazier Life Sciences Management, L.P. Allogene Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 3,868,750 shares of ALLO stock, worth $4.02 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
3,868,750
Previous 2,867,750
34.91%
Holding current value
$4.02 Million
Previous $6.11 Million
7.53%
% of portfolio
0.36%
Previous 0.37%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
180Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$19.5 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$17.1 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$12.8 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$11.5 Million5.97% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.4MShares$10.9 Million1.06% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $150M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...